中成药即将告别“尚不明确”

Core Viewpoint - The implementation of the new regulation by the National Medical Products Administration (NMPA) will phase out traditional Chinese medicine (TCM) products with ambiguous safety information, marking a significant shift towards quality over quantity in the TCM industry [1][4]. Group 1: Regulation Impact - The new regulation, referred to as the "life and death clause" for TCM, will take effect on July 1, 2026, and will disallow re-registration of TCM products that have any safety information marked as "unclear" after a three-year grace period [1][4]. - Over 70% of the approximately 57,000 approved TCM products currently have safety information issues, which will lead to a significant reduction in market products, estimated at 30%-40% [2][4]. Group 2: Consumer Safety - Existing TCM products, such as Ban Lan Gen and Lianhua Qingwen, will not be directly affected by the new regulation, allowing consumers to continue using them [3]. - Companies are proactively investing in post-marketing safety evaluations to ensure compliance with the new standards before the deadline [3]. Group 3: Industry Transformation - The regulation signifies a transition for the TCM industry from a focus on quantity to prioritizing quality, with an expected 20%-30% of TCM approvals likely to exit the market in the next 3-5 years [4]. - The cost of compliance for companies may increase due to the need for safety evaluations, but this is not expected to lead to widespread price hikes for TCM products [5][6]. Group 4: Market Dynamics - The market concentration is expected to increase as low-market-share products exit, allowing leading companies to fill the gap with quality products [6]. - The NMPA has established communication mechanisms to support companies in their research efforts and expedite the review process for critical products [6].